Zhejiang Tailin BioEngineering Co.,Ltd (SHE:300813)
China · Delayed Price · Currency is CNY 20.48
+0.23 (1.14%)
Aug 14, 2026, 3:04 PM CST
SHE:300813 Revenue
Zhejiang Tailin BioEngineering Co.,Ltd had revenue of 70.06M CNY in the quarter ending March 31, 2026, with 4.67% growth. This brings the company's revenue in the last twelve months to 342.66M, up 2.00% year-over-year. In the year 2025, Zhejiang Tailin BioEngineering Co.,Ltd had annual revenue of 339.54M, down -2.71%.
Revenue (ttm)
342.66M
Revenue Growth
+2.00%
P/S Ratio
7.24
Revenue / Employee
433.75K
Employees
790
Market Cap
2.48B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 339.54M | -9.46M | -2.71% |
| Dec 31, 2024 | 349.00M | 79.14M | 29.33% |
| Dec 31, 2023 | 269.86M | -104.02M | -27.82% |
| Jan 1, 2023 | 373.88M | 90.63M | 32.00% |
| Jan 1, 2022 | 283.25M | 83.01M | 41.46% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Kehua Bio-Engineering Co.,Ltd | 1.65B |
| Dirui Industrial | 864.90M |
| Chison Medical Technologies | 435.38M |
| Nanjing Medlander Medical Technology | 412.52M |
| Jiangsu Canopus Wisdom Medical Technology | 399.78M |
| Tellgen | 371.54M |
| Kontour (Xi'an) Medical Technology | 342.27M |
| Beijing Leadman Biochemistry | 317.86M |